Tag Archive for: RNA

STORM Therapeutics publishes data in Cancer Discovery showing induction of anti-tumour immunity by METTL3 inhibition

/in

Pre-clinical data strongly supports progression of a METTL3 inhibitor in an immuno-oncology setting. STC-15 is the first molecule specifically targeting METTL3 to enter clinical development. 8 August 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and […]

Read more

STORM Therapeutics Presents STC-15 Preclinical Data Supporting Treatment of Patients with AML at the AACR Acute Myeloid Leukemia and Myelodysplastic Syndrome Conference

/in

Data demonstrates that STC-15, an oral METTL3 inhibitor, exhibits efficacy as a single agent and in combination with venetoclax using patient-derived tumor models STC-15 Phase 1 study in solid tumors aims to identify doses and regimen for potential clinical studies in AML and solid tumors 25 January 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical […]

Read more

The ‘must-attend’ Healthcare conferences of Q1 & Q2 2023

/in

… And just like that it’s ANOTHER new year! If you are still gathering your thoughts on how best to maximise your time in 2023, allow us to flag some of the most impactful and innovative conferences in Life Sciences. The Optimum team really enjoyed being back in person for the majority of the conferences […]

Read more

STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study

/in

23 November 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announces that the first patient has been dosed with STC-15, the Company’s first-in-class clinical candidate. Read more…

Read more

STORM Therapeutics: 2022 Winner of “Fierce 15”

/in

The award highlights significant company growth and advancement in the field of RNA modifying enzymes (RME) as STORM aims to become the global leader in the field of RME.

Read more
© Optimum Strategic Communications.